Improving lives
Optimizing CNS drug discovery
About NeuCyte
NeuCyte is a biotech company focused on generating quality iPSC-derived neural cells to develop treatments for neurological disorders. Our vision and approach span many biopharmaceutical sectors as our technology is utilized to find treatments and solutions for AD, ALS/FTD, rare diseases and disorders, epilepsy, autism and other neurodegenerative diseases. ​​​
What started with an idea has now advanced to an advantageous, proprietary human iPSC-based technology platform for CNS disease modeling, target validation, custom cell production, and compound screening. With both human biology and high throughput screening our system can be used to develop therapeutic agents of a wide variety for many disease areas.
​
Our robust platform allows us to differentiate iPS cells from any background into a range of neural cell types, including neurons, astrocytes, and microglia with a 100% success rate. Our assay capabilities include a wide range of electrophysiology and high content imaging systems, as well as genomic and biochemical analysis, the combination of which provide neural functional assessment for our clients. This powerful and comprehensive foundation makes the NeuCyte platform a rigorous and reproducible system that can be used to screen therapeutic agents of a wide variety for many disease areas, with significant interest and effort to help serve rare disease communities.
Leadership Team
Scientific Advisory Board
Paul J. Hagerman, MD, PhD
Distinguished Professor in Biochemistry and Molecular Medicine, University of California at Davis
​
Pamela Lein, PhD
Department Chair and Professor, Molecular Biosciences, School of Veterinary Medicine, University of California at Davis
​
Zhiping P. Pang, MD, PhD
Associate Professor of Neuroscience and Cell Biology
Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School
​
Julia TCW, PhD
Assistant Professor of Pharmacology and Bioinformatics,
Director and Principal Investigator, Laboratory of Human Induced Pluripotent Stem Cell Therapeutics, Boston University
​
Edsel Abud, MD, PhD
Assistant Professor of Medicine Division of Allergy, Asthma and Immunology, Scripps Clinic La Jolla
​
Why Partner with NeuCyte?
Proprietary
iPSC Platform
Advanced technology for translatable neuroscience focused on neurological disorders.
SynFire
Neural Cells
Enable accurate in vitro models of neurological diseases.
Phenotypic &
Target-Based Screens
Precision tools for drug discovery and development.
Accelerated
Innovation
Partnership with NeuCyte to advance neurological treatments faster.
Expert
Team
World-class scientists dedicated to understanding human disease phenotypes for target identification.
Partnership Opportunities
NeuCyte is open to exploring strategic partnerships to accelerate our current drug discovery programs and to expand the use of our platform beyond our internal R&D programs. We are interested in pursuing other neurological disease models, technologies and drug candidates that are consistent with our core mission of helping those suffering from neurological related illnesses.
​
​
For more information, please contact us at info@neucyte.com​
​